Skip to content

Michel Sabé

17 papers in the library · 242 citations · publishing 2019-2026

Papers

Sort Most recent Most cited

Psychedelic-induced hypomania and mania: a systematic review and meta-analysis.

Molecular Psychiatry May 29, 2026 Mickael Eskinazi, Rayan Nasserdine, Romane M Cusin et al.

Serotonergic psychedelics are increasingly investigated as treatments for affective disorders. Concerns persist regarding their potential to induce hypomania or mania, particularly in individuals with bipolar spectrum vulnerability. Whether these substances precipitate transient mood switches or contribute to persistent bipolar illness or diagnostic transition remains unclear. We conducted a...

Variability in outcomes and subjective effects of psychedelic use in psychotic populations: Case-based evidence from naturalistic settings

Psychedelics May 14, 2026 Joseph T. la Torre, Jade Gallo, Matteo Buonaroti et al.

This paper presents qualitative data reported by individuals with histories of psychotic symptoms and experiences who engaged in naturalistic psychedelic use compiled as a case series. Through detailed first-person narratives, we explore how both classic and non-classic psychedelic experiences were subjectively experienced and integrated by individuals in this population, which is usually...

DOI: 10.1016/j.psyche.2026.100021 (opens in new tab) Qualitative research Categorical variable Naturalism Naturalistic observation +5

Psychedelics for treatment of negative symptoms and depressive symptoms in schizophrenia spectrum disorder: A narrative review

Schizophrenia Research March 13, 2026 Michel Sabé, Paul Grof, Nathan Sackett et al. 1 citation

Serotonergic psychedelics are re-emerging as therapeutic candidates across psychiatry, particularly for treatment-resistant depression. Their rapid and sustained antidepressant effects, alongside evidence for neuroplastic, dopaminergic, and glutamatergic modulation, have prompted interest in whether they could address depressive and negative symptoms in schizophrenia spectrum disorders (SSDs)....

Real-world effectiveness and safety of psychedelic-assisted psychotherapy: Outcomes from a large-scale compassionate use cohort in Switzerland.

Psychiatry Research February 2, 2026 Tatiana Aboulafia Brakha, Albert Buchard, Cédric Mabilais et al. 1 citation

Classic serotonergic psychedelics such as LSD and psilocybin show promising antidepressant effects in controlled trials, but real-world data from routine clinical care remain limited. This study retrospectively analysed routine data from adults with treatment-resistant depressive and/or anxiety disorders who received a first standardized Psychedelic-assisted Psychotherapy (PAP) cycle with 100...

Limited prognostic value of early maladaptive schemas for acute psychedelic experience and symptom improvement

Research Square December 1, 2025 Albert Buchard, Federico Seragnoli, Michel Sabé et al. preprint

Abstract Early maladaptive schemas (EMS) are highly prevalent in patients seeking psychedelic-assisted psychotherapy and correlate strongly with baseline depression and anxiety. This study characterized EMS in 192 adults and longitudinally followed 74 patients receiving psilocybin- or LSD-assisted therapy. We found that baseline schema burden, particularly related to failure and defectiveness,...

DOI: 10.21203/rs.3.rs-8214817/v1 (opens in new tab) Anxiety Psilocybin Schema genetic algorithms Depression economics +5

Efficacy, all-cause discontinuation, and safety of serotonergic psychedelics and MDMA to treat mental disorders: A living systematic review with meta-analysis.

European Neuropsychopharmacology November 7, 2025 Mikkel Højlund, Helin Y. Kafali, Begüm Kırmızı et al. 12 citations

Serotonergic psychedelics and 3,4-methylendioxtmethamphetamine (MDMA) are promising treatments for mental disorders with a continuously evolving evidence base. We searched Pubmed/Scopus/clinical trial registries up to 08july2025 for double-blind randomized controlled trials (RCTs) testing MDMA or serotonergic psychedelics in patients with mental disorders. Primary outcomes were change in...

DOI: 10.1016/j.euroneuro.2025.09.011 (opens in new tab) Psychedelic therapy MDMA Therapy Psychedelic medicine Entheogenic therapy +12

Microdosing Psychedelics to Restore Synaptic Density in Schizophrenia.

International Journal of Molecular Sciences September 14, 2025 Jacopo Sapienza, Marco Spangaro, Stefano Comai et al. 2 citations

Schizophrenia is a highly polygenic disease, and several genetic variants associated with the disease converge on altered synaptic homeostasis. In particular, the gene encoding complement component 4 (C4) showed the strongest association with schizophrenia, and this protein is involved in complement-dependent and microglia-mediated synaptic pruning. As a matter of fact, microglia are overactive...

Treatment approaches and efficacy in psychedelic-induced psychosis: A systematic review.

Asian Journal of Psychiatry June 26, 2025 Adi Sulstarova, Luise Scheuerlein, Silvia Monari et al. 4 citations

Psychedelics are increasingly used in the general population, yet they are associated with increased risk of psychosis in a minority of users that can experience psychedelic-induced psychosis (<1 % in controlled trial settings). In contrast, the evidence regarding the treatment of psychedelics-induced psychosis remains to date scarce. We conducted a PRISMA 2020-compliant systematic review...

Half a Century of Research for Mind–Body Interventions: A Scientometric Analysis

Mindfulness May 17, 2025 Michel Sabé, Chaomei Chen, Davy Vancampfort et al. 7 citations

Abstract Objectives We conducted a scientometric analysis on mind–body interventions to assess themes and trends in recent decades, providing insights for prospective research directions. Our systematic search, completed on 1 November, 2023, encompassed the Web of Science Core Collection and focused on scientific publications related to contemplative practices: Mindfulness, Yoga, Qi-gong,...

DOI: 10.1007/s12671-025-02592-x (opens in new tab) Full text (opens in new tab) Mindfulness Psychological intervention Public health Psychotherapist +2

Reconsidering evidence for psychedelic-induced psychosis: An overview of reviews, a systematic review, and meta-analysis of human studies

European Psychiatry April 1, 2025 Michel Sabé 3 citations

Introduction Persons with schizophrenia are currently excluded from psychedelic-assisted therapy due to concerns about psychedelic-induced acute or persistent psychotic symptoms. However, meta-analytic evidence of the precise risk for psychedelic-induced de novo and exacerbation of psychosis in people with pre-existing psychotic disorders is lacking. Objectives We conducted an overview of...

Reconsidering evidence for psychedelic-induced psychosis: an overview of reviews, a systematic review, and meta-analysis of human studies.

Molecular Psychiatry March 1, 2025 Michel Sabé, Adi Sulstarova, Alban Glangetas et al. 39 citations

Persons with schizophrenia are excluded from psychedelic-assisted therapy due to concerns about the risk of triggering or worsening psychosis. However, there is limited meta-analytic data on the risk of psychedelic-induced psychosis in individuals with pre-existing psychotic disorders. We conducted a systematic review, meta-analysis, and overview of reviews to assess the incidence of...

DOI: 10.1038/s41380-024-02800-5 (opens in new tab) Full text (opens in new tab) Schizophrenia Psychedelics Mental health Drug safety +1

Psychothérapie assistée par psychédéliques (PAP) : le modèle genevois

Annales Médico-psychologiques revue psychiatrique July 10, 2024 Federico Seragnoli, Gabriel Thorens, Louise Penzenstadler et al. 8 citations

Dans cet article, nous avons pour objectif de décrire un modèle interdisciplinaire de psychothérapie assistée par psychédéliques (PAP) que nous avons développé dans un cadre institutionnel aux hôpitaux universitaires de Genève. La psychothérapie assistée par psychédéliques (PAP) est une approche psychothérapeutique exploitant l’altération de l’état de conscience induite par une substance...

Mindfulness-based interventions for patients with schizophrenia spectrum disorders: A systematic review of the literature.

Schizophrenia Research February 1, 2024 Michel Sabé, Raoul Kohler, Natacha Perez et al.

Mindfulness-based interventions (MBIs) have emerged as secular practices, including elements of mindfulness-based stress reduction (MBSR) and mindfulness-based cognitive therapy (MBCT). While MBIs have been widely adopted for physical and mental illness, only a few available programs are explicitly adapted for psychosis. However, previous reviews have reported the vital heterogeneity regarding...

Half a Century of Research on Posttraumatic Stress Disorder: A Scientometric Analysis.

Current Neuropharmacology 2024 Michel Sabé, Chaomei Chen, Wissam El-Hage et al. 25 citations

We conducted a scientometric analysis to outline clinical research on posttraumatic stress disorder (PTSD). Our primary objective was to perform a broad-ranging scientometric analysis to evaluate key themes and trends over the past decades. Our secondary objective was to measure research network performance. We conducted a systematic search in the Web of Science Core Collection up to 15 August...

Psilocybin-assisted therapy for depression: A systematic review and dose-response meta-analysis of human studies

European Neuropsychopharmacology August 7, 2023 Natacha Perez, Florent Langlest, Luc Mallet et al. 85 citations

Psilocybin is increasingly studied for its antidepressant effect, but its optimal dosage for depression remains unclear. We conducted a systematic review and a dose-response meta-analysis to find the optimal dosage of psilocybin to reduce depression scores. Following our protocol (CRD 42022220190) multiple electronic databases were searched from their inception until February 2023, to identify...

A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs.

European Neuropsychopharmacology November 1, 2022 Marco Solmi, Chaomei Chen, Charles Dauré et al. 55 citations

A scientometric analysis was realized to outline clinical research on psychedelics over the last century. Web of Science Core Collection was searched up to March 18, 2022, for publications on psychedelics. Network analyses and bibliometrics were combined, to identify research themes and trends with Bibliometrix and CiteSpace. The primary aim was to measure research trends evolution over time,...

DOI: 10.1016/j.euroneuro.2022.09.004 (opens in new tab) Full text (opens in new tab) Bibliometrix Citespace Evidence synthesis Mood disorders +6

Meditation-based mind-body therapies for negative symptoms of schizophrenia: Systematic review of randomized controlled trials and meta-analysis.

Schizophrenia Research October 1, 2019 Michel Sabé, Othman Sentissi, Stefan Kaiser

Meditation-based mind-body therapies (yoga, tai-chi, qi-gong, mindfulness) have been suggested to have a potential therapeutic effect on negative symptoms. We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs) examining effectiveness of yoga, tai-chi, qi-gong and mindfulness on negative symptoms of schizophrenia, using different databases and trial...